Founded on January 25, 2011, Jiangsu Yingke Biopharmaceutical, Co., Ltd. is located in the Taizhou National Medical Hi-tech Development Zone (China Medical City). The company is a modernized hi-tech biopharmaceutical company, which integrates research and development, production and sales. Registered capital is CNY 61 million and total investment is over CNY 200 million. The total area is 14000 square meters. The company is mainly committed to the research and development of energy drugs (enteral and parenteral nutrition drugs), anesthesia, cancer and other pharmaceutical fields. At present, the company mainly focuses on the market of narcotic drugs to create fat emulsion series products, aiming to become a benchmark company in the field of fat emulsion segmentation.
The company utilizes advanced manufacturing technologies, built in with bulk drug workshop that conforms to new GMP (2010 VERSION) , freeze-dried powder injection workshop, small-volume injection workshop , large-volume injection workshop (Multilayer co-extruded film medical infusion bag) ,soft-capsule preparations workshop, and traditional Chinese medicine extraction workshop.
In 2013, lentinan API workshop passed the new version of GMP certification, and industrialization was realized in the same year.
In 2014, the company was awarded "Top ten Science and Technology Innovation Enterprises" and "Science and Technology Smes in Jiangsu Province" by The Management Committee of Taizhou Pharmaceutical and High-tech Zone.
In 2015, the company was recognized as "National high-tech Enterprise".
In 2016, motherwort soft capsule workshop passed the new version of GMP certification, and industrialization was realized in the same year.
In 2017, it was awarded the pilot unit of genuine goods commitment.
In 2019, it passed the evaluation of national management system of integration of industrialization and industrialization, and undertook the provincial scientific and technological achievements transformation project.
In 2020, Propofol Medium and Long Chain Fat Emulsion Injection and Propofol Injectable Emulsion have successively obtained the registration approval, both of generic drugs and consistency evaluation are all the first approved in China. The products are the the ones recorded in National Essential Drug Catalog and National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog, which are characterized by high technical barriers and large market capacity. From October 27 to 29, 2020, the injection workshop carried out GMP compliance inspection, and was approved to go on the market on December 14, marking the industrialization of the two heavyweight varieties.
On February 3, 2021, Propofol Medium and Long Chain Fat Emulsion Injection was selected as the fourth batch of national centralized drug procurement catalogue, which accelerated the marketization process of this variety.
After ten years of hard work, the company is about to enter a stage of rapid development.. All Yingke people deeply cultivate the career of ‘Big Health’, and do a good job as the health guard of Chinese people!